BioXcel Therapeutics (BTAI) Net Income towards Common Stockholders (2017 - 2026)

BioXcel Therapeutics' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$14.2 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 2.87% year-over-year to -$14.2 million in Q1 2026; TTM through Mar 2026 was -$66.3 million, a 10.84% decrease from a year earlier, with the FY2025 full-year figure at -$66.4 million, up 74.15% from the prior year.
• Net Income towards Common Stockholders rose to -$14.2 million in Q1 2026 per BTAI's latest filing, from -$14.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$7.2 million in Q4 2024 and bottomed at -$169.8 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$22.1 million (2023), against an average of -$43.6 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 549.88% in 2022 and soared 87.01% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$169.8 million in 2022, then surged by 87.01% to -$22.1 million in 2023, then surged by 67.17% to -$7.2 million in 2024, then sank by 98.27% to -$14.4 million in 2025, then gained by 1.02% to -$14.2 million in 2026.
• Per Business Quant, the three latest BTAI Net Income towards Common Stockholders figures stand at -$14.2 million (Q1 2026), -$14.4 million (Q4 2025), and -$17.9 million (Q3 2025).